Cargando…

The role of faecal microbiota transplantation: looking beyond Clostridioides difficile infection

Faecal microbiota transplantation (FMT) is the transfer of screened and minimally processed faecal material from a ‘healthy’ donor to ‘diseased’ recipient. It has an established role, and is recommended as a therapeutic strategy, in the management of recurrent Clostridioides difficile infection (CDI...

Descripción completa

Detalles Bibliográficos
Autores principales: D. Goldenberg, Simon, Merrick, Blair
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7841662/
https://www.ncbi.nlm.nih.gov/pubmed/33614028
http://dx.doi.org/10.1177/2049936120981526
_version_ 1783643855098216448
author D. Goldenberg, Simon
Merrick, Blair
author_facet D. Goldenberg, Simon
Merrick, Blair
author_sort D. Goldenberg, Simon
collection PubMed
description Faecal microbiota transplantation (FMT) is the transfer of screened and minimally processed faecal material from a ‘healthy’ donor to ‘diseased’ recipient. It has an established role, and is recommended as a therapeutic strategy, in the management of recurrent Clostridioides difficile infection (CDI). Recognition that gut dysbiosis is associated with, and may contribute to, numerous disease states has led to interest in exploiting FMT to ‘correct’ this microbial imbalance. Conditions for which it is proposed to be beneficial include inflammatory bowel disease, irritable bowel syndrome, liver disease and hepatic encephalopathy, neuropsychiatric conditions such as depression and anxiety, systemic inflammatory states like sepsis, and even coronavirus disease 2019. To understand what role, if any, FMT may play in the management of these conditions, it is important to consider the potential risks and benefits of the therapy. Regardless, there are several barriers to its more widespread adoption, which include incompletely understood mechanism of action (especially outside of CDI), inability to standardise treatment, disagreement on its active ingredients and how it should be regulated, and lack of long-term outcome and safety data. Whilst the transfer of faecal material from one individual to another to treat ailments or improve health has a history dating back thousands of years, there are fewer than 10 randomised controlled trials supporting its use. Moving forward, it will be imperative to gather as much data from FMT donors and recipients over as long a timeframe as possible, and for trials to be conducted with rigorous methodology, including appropriate control groups, in order to best understand the utility of FMT for indications beyond CDI. This review discusses the history of FMT, its appreciable mechanisms of action with reference to CDI, indications for FMT with an emerging evidence base above and beyond CDI, and future perspectives on the field.
format Online
Article
Text
id pubmed-7841662
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-78416622021-02-19 The role of faecal microbiota transplantation: looking beyond Clostridioides difficile infection D. Goldenberg, Simon Merrick, Blair Ther Adv Infect Dis Review Faecal microbiota transplantation (FMT) is the transfer of screened and minimally processed faecal material from a ‘healthy’ donor to ‘diseased’ recipient. It has an established role, and is recommended as a therapeutic strategy, in the management of recurrent Clostridioides difficile infection (CDI). Recognition that gut dysbiosis is associated with, and may contribute to, numerous disease states has led to interest in exploiting FMT to ‘correct’ this microbial imbalance. Conditions for which it is proposed to be beneficial include inflammatory bowel disease, irritable bowel syndrome, liver disease and hepatic encephalopathy, neuropsychiatric conditions such as depression and anxiety, systemic inflammatory states like sepsis, and even coronavirus disease 2019. To understand what role, if any, FMT may play in the management of these conditions, it is important to consider the potential risks and benefits of the therapy. Regardless, there are several barriers to its more widespread adoption, which include incompletely understood mechanism of action (especially outside of CDI), inability to standardise treatment, disagreement on its active ingredients and how it should be regulated, and lack of long-term outcome and safety data. Whilst the transfer of faecal material from one individual to another to treat ailments or improve health has a history dating back thousands of years, there are fewer than 10 randomised controlled trials supporting its use. Moving forward, it will be imperative to gather as much data from FMT donors and recipients over as long a timeframe as possible, and for trials to be conducted with rigorous methodology, including appropriate control groups, in order to best understand the utility of FMT for indications beyond CDI. This review discusses the history of FMT, its appreciable mechanisms of action with reference to CDI, indications for FMT with an emerging evidence base above and beyond CDI, and future perspectives on the field. SAGE Publications 2021-01-25 /pmc/articles/PMC7841662/ /pubmed/33614028 http://dx.doi.org/10.1177/2049936120981526 Text en © The Author(s), 2021 https://creativecommons.org/licenses/by/4.0/ This article is distributed under the terms of the Creative Commons Attribution 4.0 License (https://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Review
D. Goldenberg, Simon
Merrick, Blair
The role of faecal microbiota transplantation: looking beyond Clostridioides difficile infection
title The role of faecal microbiota transplantation: looking beyond Clostridioides difficile infection
title_full The role of faecal microbiota transplantation: looking beyond Clostridioides difficile infection
title_fullStr The role of faecal microbiota transplantation: looking beyond Clostridioides difficile infection
title_full_unstemmed The role of faecal microbiota transplantation: looking beyond Clostridioides difficile infection
title_short The role of faecal microbiota transplantation: looking beyond Clostridioides difficile infection
title_sort role of faecal microbiota transplantation: looking beyond clostridioides difficile infection
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7841662/
https://www.ncbi.nlm.nih.gov/pubmed/33614028
http://dx.doi.org/10.1177/2049936120981526
work_keys_str_mv AT dgoldenbergsimon theroleoffaecalmicrobiotatransplantationlookingbeyondclostridioidesdifficileinfection
AT merrickblair theroleoffaecalmicrobiotatransplantationlookingbeyondclostridioidesdifficileinfection
AT dgoldenbergsimon roleoffaecalmicrobiotatransplantationlookingbeyondclostridioidesdifficileinfection
AT merrickblair roleoffaecalmicrobiotatransplantationlookingbeyondclostridioidesdifficileinfection